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Abstract
Background: CJ9-gD is a novel dominant-negative recombinant herpes simplex virus type 1 (HSV-1) that is completely 
replication-defective, cannot establish detectable latent infection in vivo, and expresses high levels of the major HSV-1 
antigen glycoprotein D immediately following infection. In the present study, CJ9-gD was evaluated as a vaccine 
against HSV-2 genital infection in guinea pigs.
Results: Animals immunized with CJ9-gD developed at least 700-fold higher titers of HSV-2-specific neutralization 
antibodies than mock-immunized controls. After challenge with wild-type HSV-2, all 10 control guinea pigs developed 
multiple genital lesions with an average of 21 lesions per animal. In contrast, only 2 minor lesions were found in 2 of 8 
CJ9-gD-immunized animals, representing a 40-fold reduction on the incidence of primary genital lesions in immunized 
animals (p < 0.0001). Immunization significantly reduced the amount and duration of viral shedding and provided 
complete protection against neurological symptoms, while 90% of mock-immunized animals succumbed due to the 
severity of disease. Importantly, immunized animals showed no signs of recurrent disease or viral shedding during a 60-
days observation period after recovery from primary infection, and carried 50-fold less latent viral DNA load in their 
dorsal root ganglia than the surviving mock-vaccinated controls (p < 0.0001).
Conclusions: Collectively, we demonstrate that vaccination with the HSV-1 recombinant CJ9-gD elicits strong and 
protective immune responses against primary and recurrent HSV-2 genital disease and significantly reduces the extent 
of latent infection.
Background
Genital herpes is the main cause of genital ulcer disease
worldwide and is due to infections with herpes simplex
virus (HSV) [1,2]. HSV-2 accounts for most cases of geni-
tal herpes [3]. Recent studies indicate that in developed
countries HSV-1 has become the main causative agent for
primary genital herpes, especially among adolescents,
women, and homosexual men [4-7]. The prevalence of
HSV-2 in the general population ranges from 10%-60%,
indicating that genital herpes is one of the most common
sexually transmitted diseases [2,8].
After primary genital infection, HSV establishes latent
infection in dorsal root ganglia with lifelong persistence,
subsequently giving rise to intermittent reactivation and
recurrent disease [9]. As the clinical appearance of genital
HSV infection varies from unspecific symptoms to typi-
cally painful lesions [10], only 10-25% of people who are
seropositive for HSV-2 are aware that they have genital
herpes. HSV is intermittently shed from the genital
mucosa in the absence of symptoms causing subcon-
scious transmission of disease [11]. Vertical transmission
of HSV to neonates is associated with a high mortality
rate and a high incidence of neurological sequelae in sur-
vivors [12]. In addition, genital herpes has been linked to
an increased risk of sexually acquiring and transmitting
human immunodeficiency virus (HIV), which can be
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strongly reduced by HSV antiviral therapy [13,14]. To
date, the treatment and prevention of primary and recur-
rent disease is limited [15]. Experimental vaccine
approaches against genital herpes have included pep-
tides, proteins, killed virus, DNA vaccines, heterologous
replicating viral vectors, replication-defective viruses,
and attenuated replication-competent viruses [16,17].
Considering the general impact of HSV-1 diseases and
rising importance of primary genital herpes caused by
HSV-1, a desirable vaccine should be capable of offering
effective protective immunity against both HSV subtypes.
A main target for subunit vaccine development has
been HSV glycoprotein D (gD), a major antigen on the
viral envelope [17]. Subunit vaccines containing gD in
combination with an adjuvant appeared to be safe and
effective against genital herpes in guinea pigs [18-20], but
failed to provide general protection in clinical trials
[21,22]. Replication-defective viruses lacking functions
essential for viral replication or assembly of progeny virus
particles have a broad antigenic spectrum and are more
efficient than subunit vaccines in eliciting protective
immune responses against genital HSV in mice and
guinea pigs [23]. However, the use of replication-defec-
tive viruses, particularly when used in latently infected
individuals, imposes certain risks, as they might regain
replication competence in the presence of wild-type virus
or reactivate latent wild-type virus infections [24].
To minimize these safety concerns, using the T-REx™
gene switch technology (Invitrogen, Carlsbad, CA) devel-
oped in our laboratory and the dominant-negative
mutant polypeptide UL9-C535C of HSV-1 origin binding
protein UL9, we generated a novel class of replication-
defective HSV-1 recombinant, CJ83193, which can pre-
vent its own viral DNA replication as well as that of wild-
type HSV-1 and HSV-2 in co-infected cells [25,26]. To
increase its safety and vaccine efficacy against HSV infec-
tions, we recently constructed a CJ83193-derived HSV-1
recombinant CJ9-gD by replacing the essential UL9 gene
with an extra copy of the HSV-1 gD (gD1) gene under the
control of the tetO-bearing hCMV major immediate-
early promoter [27]. We demonstrated that unlike the gD
gene controlled by the endogenous promoter whose
expression is dependent on viral replication [28], CJ9-gD
expresses high-levels of gD at the immediate-early phase
of HSV infection. Moreover, CJ9-gD is completely repli-
cation-defective and causes no detectable infection in
trigeminal ganglia after ocular or nasal infection in mice
[27]. In mice, CJ9-gD induces strong and long-lasting
humoral and Th1-associated cellular immune responses
against HSV-1 and HSV-2 [27,29]. Immunization with
CJ9-gD protects mice against HSV-1 ocular keratitis and
guinea pigs against HSV-1 skin disease [27,30] as well as
genital herpetic disease caused by wild-type HSV-1 and
HSV-2 in mice [29]. Previously, we have shown further
that CJ9-gD is a safer and more effective vaccine than
non-gD-expressing parental CJ83193 virus against HSV-1
infection [27,29].
The guinea pig model of HSV-2 genital infection offers
a unique advantage over the mouse model to investigate
the efficacy of candidate HSV vaccine in protection
against primary and recurrent HSV-2 genital infection
and disease. Specifically, following primary intravaginal
infection with HSV-2, guinea pigs develop vesicular
lesions resembling those in humans, including develop-
ment, appearance, and duration of disease. In contrast to
mice in which spontaneous reactivation from latent
infection rarely occurs in the vaginal tract, guinea pigs
undergo episodic spontaneous recurrent infection and
disease after recovering from initial genital disease
[31,32]. In the current report, we investigate whether
CJ9-gD can serve as an effective vaccine in protection
against both primary and recurrent HSV-2 genital infec-
tion and disease in guinea pigs following intravaginal
challenge with wild-type HSV-2.
Results
Induction of HSV-2-specific neutralization antibodies
The ability of CJ9-gD to elicit HSV-2-specific neutraliz-
ing antibodies was determined (Fig. 1). The HSV-2-spe-
cific neutralization antibody titer was detected in serum
from all immunized guinea pigs and increased signifi-
cantly from the first to the second vaccination (p < 0.005)
with a peak titer 3 weeks after the second vaccination of
1400. No HSV-2-specific neutralization antibody was
detected in serum from mock-immunized animals at 1:2-
dilution before challenge. After challenge with the wild-
type HSV-2, the neutralization antibody titer in immu-
nized animals increased 2-fold (p > 0.05) and was 1.5-fold
Figure 1 Induction of HSV-2-specific neutralizing antibodies in 
immunized guinea pigs. Two sets of guinea pigs (n = 8; n = 10) were 
injected s.c. with 5 × 106 PFU/animal of CJ9-gD or with DMEM and 
boosted after 3 weeks. Blood was taken 3 weeks after each immuniza-
tion and 5 weeks after challenge. After heat inactivation, serum from 
each animal was assayed separately for HSV-2-specific neutralizing an-
tibody titers on Vero cell monolayers. The results represent average ti-
ters ± SEM. P-value was assessed by Student's t-test (* p < 0.005).
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higher than that in mock-immunized controls following
challenge.
Reduction of intravaginal replication of challenge HSV-2 in 
immunized guinea pigs
Six weeks after the initial immunization, two sets of
guinea pigs (n = 8; n = 10), which were either mock-
immunized (n = 10) or immunized with 5 × 106 PFU of
CJ9-gD (n = 8), were challenged intravaginally with wild-
type HSV-2 strain MS. To examine the effectiveness of
immunization with CJ9-gD against intravaginal replica-
tion of challenge HSV-2, vaginal swabs were taken on
days 1, 2, 3, 5, 7 and 9 after challenge. As shown in Fig.
2A, the yields of challenge virus were significantly lower
in immunized guinea pigs compared with those in mock-
immunized controls from days 1 to 7 (p-values for days 1,
2, and 3 < 0.05, p-value for days 5 and 7 < 0.005), with a
reduction of 207-fold on day 1 (p = 0.036) and 220-fold
on day 2 (p = 0.012). By day 9 no challenge virus was
detected in CJ9-gD-immunized guinea pigs, whereas 50%
of mock-immunized animals continued to shed virus at
an overall average yield of more than 7.1 × 102 PFU/ml.
Compared with mock-immunized controls, the average
duration of viral shedding in immunized guinea pigs
decreased markedly from more than 8 days to 3.6 days
(Fig. 2B, p < 0.0005).
Protection against primary HSV-2 genital disease in 
immunized guinea pigs
After intravaginal challenge with wild-type HSV-2, ani-
mals were monitored daily for signs of disease. The devel-
opment and clinical appearance of lesions caused by
challenge virus in mock-vaccinated guinea pigs was con-
sistent with previous observations.
The impact of immunization with CJ9-gD on the inci-
dence of skin lesions is summarized in Fig. 3. All 10
mock-immunized guinea pigs (100%) developed multiple
genital herpes lesions following challenge with wild-type
HSV-2. In contrast, only 2 of 8 animals immunized with 5
× 106 PFU of CJ9-gD exhibited two mild herpetiform
lesions, resulting in an average of 0.5 lesions per immu-
nized animal. In the corresponding control group, an
average of 20.6 lesions per mock-vaccinated animal was
detected on day 6 post-challenge (p < 0.0001). Thus, the
overall incidence of primary herpetic skin lesions in
immunized animals was reduced 40-fold compared to
mock-immunized controls. Moreover, the two lesions
found in the above mentioned immunized guinea pigs
were less pronounced and healed off within 2 to 6 days,
whereas in mock-immunized animals lesions turned into
Figure 2 Reduction of challenge HSV-2 vaginal replication in 
guinea pigs immunized with CJ9-gD. One set of 8 and one set of 10 
guinea pigs were inoculated s.c. with either 5 × 106 PFU/animal of CJ9-
gD or DMEM and boosted after 3 weeks. At 6 weeks guinea pigs were 
challenged intravaginally with 5 × 105 PFU of HSV-2 strain MS. Vaginal 
swabs were taken on days 1, 2, 3, 5, 7, and 9 post-challenge. Infectious 
virus in swab materials was assessed by standard plaque assay on Vero 
cell monolayers. Viral titers are expressed as the mean ± SEM in individ-
ual vaginal swabs (A). The duration of viral shedding is represented as 
the mean number of days during which infectious virus was detected 
in swab materials following challenge ± SEM (B). P-values were as-
sessed by Student's t-test (* p < 0.05, ** p < 0.005, *** p < 0.0005)
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Figure 3 Prevention of primary HSV-2 genital lesions in guinea 
pigs immunized with CJ9-gD. Mock-immunized and CJ9-gD-immu-
nized guinea pigs described in Fig. 2 were monitored daily for clinical 
symptoms following challenge with wild-type HSV-2. The average 
number of lesions per immunized animals was compared with that 
found in mock-immunized guinea pigs. The indicated values represent 
the mean number of lesions ± SD on day 6 post-challenge. P-value was 
assessed by Student's t-test (* p < 0.0001).
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macerating ulcers with prolonged healing (Fig. 4A) and
associated with systemic spreading of virus. All immu-
nized guinea pigs survived the study and showed no signs
of neurological illness, whereas 5 of 10 mock-immunized
animals (50%) were sacrificed by day 14 after challenge
due to hind limb paralysis and severity of disease. The
mortality rate in this group increased to 90% by day 41
after challenge (Fig. 4B).
Protection against recurrent HSV-2 infection in immunized 
guinea pigs
After recovery from intravaginal challenge with wild-type
HSV-2, surviving animals were monitored daily from day
30 to day 60 for signs of recurrent disease. In addition,
vaginal swabs were taken daily and assayed for the pres-
ence of infectious virus. All immunized animals, and 3 of
the 10 mock-immunized controls that survived the first
30 days following challenge with wild-type HSV-2 were
monitored for recurrent HSV-2 infection. Two of the
mock-immunized animals had recurrent viral shedding
between days 30 and 60, whereas one had recurrent
lesions. In contrast, no lesions or recurrent viral shedding
were detected in immunized guinea pigs (Table 1).
Protection from latent viral infection in immunized guinea 
pigs
At day 60 after challenge, 12 lower lumbar and sacral dor-
sal root ganglia per guinea pig were harvested from all 8
animals immunized with CJ9-gD and the 2 surviving
mock-immunized controls. The whole DNA was
extracted and tested for latent viral DNA using quantita-
tive real-time PCR. The limit of detection was 5 DNA
copies per reaction (correlation coefficient +/- SD: 0.96
+/- 0.016). As shown in Fig. 5, the average amount of
latent HSV DNA per guinea pig was 50-fold greater in
mock-vaccinated controls than in immunized animals
(261486 DNA copies vs. 5229 DNA copies, p ≤ 0.0001).
Discussion
Although to date no vaccine capable of completely pre-
venting HSV infection has been reported, it is believed
that great benefits can be obtained from developing a
vaccine that prevents disease with or without partial pro-
tection from infection as demonstrated with pertussis
and influenza virus vaccines [34]. Our earlier studies
demonstrate that immunization with CJ9-gD induces
strong and long-lasting HSV-1- as well as HSV-2-specific
humoral and Th1- cellular immune responses in mice,
leading to a significant reduction in the amount and
duration of acute replication of wild-type HSV-1 and
HSV-2 after vaginal challenge compared with mock-
immunized controls. At an immunization dose of 2 × 106
PFU of CJ9-gD, mice were completely protected from
HSV-1 and HSV-2 disease [29]. We were, however,
unable to evaluate whether immunization with CJ9-gD is
effective in protection against recurrent HSV genital
infection and disease in mice. Therefore, in the present
report we used guinea pigs to explore the efficacy of
immunization with CJ9-gD against HSV-2 primary as
well as recurrent genital infection and disease.
Figure 4 Prevention of primary HSV-2 disease in guinea pigs im-
munized with CJ9-gD. After challenge with wild-type HSV-2, individ-
ual guinea pigs described in legend of Fig. 3 were observed during a 
60-day follow-up period for the incidence of genital and disseminated 
HSV-2 disease using the following score: 0 = no disease; 1 = redness or 
swelling; 2 = a few small vesicles; 3 = several large vesicles; 4 = several 
large ulcers with maceration; 5 = paralysis; and 6 = death. Presented is 
the disease score for the first 15 days after challenge (A.) and the per-
centage of survival until day 60 after challenge (B.).
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Table 1: Prevention of recurrent HSV-2 infection in guinea 
pigs immunized with CJ9-gD
Mock (n = 3) CJ9-gD (n = 8)
Recurrency1 3/3 0/8
Recurrent lesions2 1/3 0/8
Recurrent shedding3 2/3 0/8
1 Overall number of guinea pigs with recurrent lesions and/or 
recurrent shedding between days 30 and 60 after challenge.
2 Number of guinea pigs with recurrent genital lesion between 
days 30 and 60 after challenge.
3 Number of guinea pigs from which virus was detected in 
vaginal swab material by plaque assay on Vero cell monolayers 
between days 30 and 60 after challenge.Brans and Yao BMC Microbiology 2010, 10:163
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We demonstrate that immunization with CJ9-gD at a
dose of 5 × 106 PFU elicits high levels of neutralizing anti-
bodies against HSV-2 in guinea pigs. Titers increased sig-
nificantly from the first to the second vaccination,
indicating a boosting effect. Like in mice [29], immuniza-
tion with CJ9-gD induced about 7-fold higher neutraliza-
tion antibody titers in guinea pigs against HSV-1 than
HSV-2 (p < 0.0001) (data not shown). In the present study
cellular immune responses were not tested due to the lack
of sufficient immunological reagents specific for guinea
pigs. We did, however, demonstrate in mice that immuni-
zation with CJ9-gD elicits strong HSV-specific CD4+ and
CD8+  T-cell responses against HSV-1 and in a lesser
extent against HSV-2 at levels similar or comparable to
those induced by wild-type HSV-1 [27,29]. Given the
demonstrated importance for both HSV-specific CD4+
and CD8+ T cells in clearance of virus from infected epi-
thelium and in neural tissues in the mouse model of HSV
infections [35-40], it is not surprising that HSV-2 cross-
specific-T cell response elicited in CJ9-gD-immunized
guinea pigs plays a critical role in limiting the replication
of challenge virus during both primary infection and
reactivation from latency.
Immunization with CJ9-gD significantly reduced the
amount and duration of wild-type virus replication as
well as the number of genital lesions after vaginal chal-
lenge with HSV-2 compared with that in mock-immu-
nized guinea pigs. Only 2 of 8 immunized animals
developed 2 mild and fast healing herpetiform lesions
with no signs of systemic involvement. Morbidity was
quite extensive in mock-vaccinated animals with an aver-
age of 20.6 lesions per animal, a high incidence of sys-
temic involvement, and a mortality rate of 90%. High
mortality rates in mock-vaccinated animals after vaginal
challenge with wild-type HSV-2 have been reported by
other groups [19,41] and limit the evaluation of recur-
rences. The extent of disease might be influenced by the
viral strain or stock, the viral titer and by the inoculation
method used. Despite the extensive disease in mock-vac-
cinated animals, CJ9-gD provided good protection
against genital challenge with wild-type HSV-2 in immu-
nized guinea pigs. Therefore, it is reasonable to anticipate
that protection would be more effective should a lower
dose of challenge virus or a more gentle inoculation be
selected.
In accordance with the protection against primary dis-
ease, neither recurrent vaginal shedding of infectious
virus nor recurrent genital lesions were found in CJ9-gD-
immunized animals. Quantitative PCR analysis shows
that the amount of latent HSV DNA in dorsal root ganglia
was 50-fold lower in immunized guinea pigs compared
with the 2 mock-immunized guinea pigs that survived
following challenge with wild-type HSV-2 (p < 0.0001).
Recall that CJ9-gD cannot establish detectable latent
infection in sensory ganglia in mice following ocular or
intranasal infection [27] nor in dorsal root ganglia after
subcutaneous immunization [29]. The viral DNA
detected in dorsal root ganglia of CJ9-gD-immunized
guinea pigs after vaginal challenge should be primarily
the challenge wild-type HSV-2 viral DNA. Taken
together, these results are consistent with observations
that a reduced latent infection is associated with a lower
incidence of reactivation and recurrent disease
[20,41,42].
Several vaccine candidates have been tested in guinea
pigs against genital HSV-2 infection. The subunit vaccine
gD2/AS04, which contains the HSV-2 major antigen gly-
coprotein D (gD2) in combination with the adjuvant alu-
minium hydroxide and 3-O-deacylated-monophosphoryl
lipid A (MPL), was effective in prevention of primary and
recurrent genital disease in immunized animals following
challenge with wild-type HSV-2 [19,20]. In phase 3 clini-
cal trials, however, it only provided 73-74% efficacy in
protecting against development of genital herpes disease
in HSV-seronegative women [21]. A recent study showed
that the replication-defective HSV-2 recombinant dl5-29
was more effective than the HSV-2-gD-based subunit
vaccine in inducing HSV-2-specific neutralizing antibod-
ies and CD8+ T-cell response in mice [43]. CJ9-gD is an
HSV-1 recombinant defective at level of viral DNA repli-
cation, and therefore, similar to dl5-29, capable of
expressing a broad spectrum of viral antigens. In addi-
tion, it has a unique dominant-negative effect on viral
replication (UL9-C535C expression) and expresses high
levels of the major HSV-1 antigen gD at the immediate-
Figure 5 Protection from latent viral infection in guinea pigs im-
munized with CJ9-gD. Sixty days after challenge, 12 lower lumbar 
and sacral dorsal root ganglia (DRG) per guinea pig were harvested 
from all 8 immunized guinea pigs and the 2 surviving mock-immu-
nized controls. The whole DNA was extracted and quantified for the 
presence of latent viral DNA using quantitative real-time PCR. The 
amount of viral DNA per guinea pig (A) was determined. The results are 
indicated as mean values ± SEM. P-value was assessed by Student's t-
test (* p < 0.0001).
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early phase of infection [27]. Immunization with CJ9-gD
led to 220-fold reduction in the yield of challenge wild-
type HSV-2 in genital swabs materials on day 2 post-chal-
lenge compared with mock-immunized controls. Noting
that immunization with gD2/AS04 resulted in less than
14-fold challenge wild-type HSV-2 (strain MS) viral repli-
cation compared with mock-immunized controls on day
2 post-challenge, and all mock-immunized animals sur-
vived after recovery from primary disease caused by chal-
lenge virus [20], our study suggests that CJ9-gD could
potentially be more efficacious than gD2 subunit vaccine
against HSV-2 genital disease. It will be interesting to test
the vaccine efficacy of gD2/AS04 and CJ9-gD in protect-
ing against HSV-2 genital herpes in the same experimen-
tal settings. Moreover, in light of that CJ9-gD expresses
high-level of gD, and induction of both effective mucosal
and systemic immune responses is likely required for an
optimal protection against HSV genital infection, it
would be of great interest to investigate the effectiveness
of CJ9-gD in induction of humoral and T-cell immunity
following different routes of immunization and whether
the efficacy of CJ9-gD in eliciting mucosal immune
response can be enhanced by gD subunit prime/CJ9-gD
boost regimen involving combination of mucosal and sys-
temic immunization [44-46].
Many type-common and type-specific antibodies as
well as T cell epitopes have been identified against vari-
ous HSV-1 and HSV-2 proteins. Mice immunized with
CJ9-gD develop stronger humoral and cellular immune
responses against HSV-1 than against HSV-2, and are sig-
nificantly better protected against genital infection with
HSV-1 than with HSV-2 [29]. These findings are in agree-
ment with the previous reports that in rodents HSV vac-
cines are generally less effective in prevention of
heterotypic HSV infection than homotypic infection
[47,48]. Combined with observations that humans who
were previously infected with HSV-2 are less likely to
experience re-infection with a heterologous strain of
HSV-2 than individuals with prior HSV-1 infection [49-
53], it is reasonable to believe, that a CJ9-gD-like domi-
nant-negative HSV-2 recombinant would be more effec-
tive in prevention of genital HSV-2 infection than the
HSV-1 recombinant CJ9-gD. This HSV-2 recombinant is
currently being devised.
Conclusions
We demonstrate that immunization with a replication-
defective and dominant-negative HSV-1 recombinant
CJ9-gD expressing high levels of gD can induce strong
cross-protective immunity against primary and recurrent
HSV-2 genital infection and disease in guinea pigs. We
show further that the latent viral load of challenge wild-
type HSV-2 is significantly reduced in immunized guinea
pigs compared with the mock-immunized controls. Col-
lectively, CJ9-gD represents a new class of HSV-1 recom-
binant, which is avirulent, unable to establish detectable
latent infection in vivo, and serves as an effective vaccine
against genital HSV infection and disease in both mice
and guinea pigs.
Methods
Animals
Female Hartley guinea pigs (300-350 g) were obtained
from Charles River Breeding Laboratories (Wilmington,
MA). The described animal experiments were conducted
according to the protocols approved by the Harvard
Medical Area Standing Committee on Animals and the
American Veterinary Medical Association. The Harvard
Medical School animal management program is accred-
ited by the Association for Assessment and Accreditation
of Laboratory Animal Care (AAALAC) and meets
National Institutes of Health standards as set forth in
"The Guide for the Care and Use of Laboratory Animals"
(National Academy Press, 1996).
Cells and viruses
African Green Monkey Kidney (Vero) cells and RUL9-8
cells, a cell line derived from U2OS cells expressing UL9
and the tetracycline repressor (tetR), were grown and
maintained in DMEM growth medium as previously
described [33].
Wild-type HSV-2 MS strain (ATCC, Manassas, VA)
was propagated and plaque assayed on Vero cells. CJ9-gD
was derived from CJ83193 by replacing the essential UL9
gene with the HSV-1 gD gene driven by the tetO-contain-
ing hCMV major immediate-early promoter [27].
CJ83193 is a replication-defective virus, in which both
copies of the HSV-1 ICP0 gene were replaced by DNA
sequences encoding the dominant-negative HSV-1 poly-
peptide UL9-C535C under control of the tetO-bearing
hCMV major immediate-early promoter [25]. CJ9-gD
was propagated and plaque assayed in RUL9-8 cells.
Immunization and challenge
One set of 8 guinea pigs and one set of 10 guinea pigs
were randomly assigned to 2 groups. Animals were either
mock-immunized with DMEM (n = 10) or immunized
with 5 × 106 PFU of CJ9-gD (n = 8) in a volume of 50 μl
s.c. in the right and left upper flank per guinea pig. On
day 21 after primary immunization, animals were
boosted. At the same time and one day prior to viral chal-
lenge, serum was obtained from saphenous veins and
stored at -80°C. Six weeks after the initial immunization,
the animals were preswabbed with a moist sterile calcium
alginate swab (Fisher Scientific, Waltham, MA) and inoc-
ulated intravaginally with 100 μl of culture medium con-
taining 5 × 105 PFU of HSV-2 strain MS. Animals wereBrans and Yao BMC Microbiology 2010, 10:163
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kept on their backs with their rear part elevated under the
influence of anesthesia for 30-45 min post-infection.
Detection of HSV-2-specific neutralization antibody titers
Blood was obtained from the saphenous veins and neu-
tralization antibody titers were determined in the pres-
ence of complement as described previously [28,30].
Clinical observations
After challenge with wild-type HSV-2 strain MS, the ani-
mals were monitored daily until day 60. The number of
lesions were counted and the progress of disease was
scored using a modified method [31]: 0 = no disease; 1 =
redness or swelling; 2 = a few small vesicles; 3 = several
large vesicles; 4 = several large ulcers with maceration; 5
= paralysis; and 6 = death.
Assay of acute and recurrent vaginal shedding of challenge 
virus
After challenge with wild-type HSV-2 strain MS, vaginal
mucosae were swabbed with a moist calcium alginate
swab (Fisher Scientific, Waltham, MA) on days 1, 2, 3, 5, 7
and 9. From days 30 to 60 post challenge swabs were
taken daily. Swabs were kept in 1 ml DMEM and stored at
-80°C until assayed for infectious virus by standard
plaque assay on Vero cell monolayers.
Quantitative real-time PCR
At day 60 after intravaginal challenge with HSV-2 strain
MS, 12 lower lumbar and sacral dorsal root ganglia were
collected from each of the surviving guinea pigs. Dorsal
r o o t  g a n g l i a  w e r e  k e p t  s e p a r a t e l y  i n  0 . 5  m l  o f  n o r m a l
growth medium and stored at -80°C for further process-
ing. DNA was isolated from each dorsal root ganglion
and assayed for viral DNA by quantitative real-time PCR
as described previously [27].
Statistical analysis
For statistical analysis unpaired Student's t-tests were
performed.
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